- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00756548
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
December 3, 2013 updated by: Braintree Laboratories
This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
386
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Research Institute
-
Orange, California, United States, 92869
- Advanced Clinical Research Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Medical Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- Gastrointestinal Associates
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- Options Health Research
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Northwest Gastroenterology Clinic
-
-
Tennessee
-
Franklin, Tennessee, United States, 37067
- Franklin Gastroenterology
-
Germantown, Tennessee, United States, 38138
- Memphis Gastroenterology Group
-
Nashville, Tennessee, United States, 37203
- The Frist Clinic
-
-
Texas
-
Houston, Texas, United States, 77090
- Houston Medical Research Associates
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
- Charlottesville Medical Research
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Northwest Gastroenterology Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
- Evaluation of barium enema results
- GI bleeding
- Anemia of unknown etiology
- Neoplastic disease surveillance
- Abnormal Endosonography
- Inflammatory bowel disease
- Unknown diarrhea or constipation etiology
- Polypectomy
- Laser therapy
- Routine screening
- At least 18 years of age.
- Otherwise in good health, as determined by physical exam and medical history.
- If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intra-uterine device, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
- Negative urine pregnancy test at screening, if applicable.
- In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study.
Exclusion Criteria:
- Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
- Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- Subjects who are undergoing colonoscopy for foreign body removal or decompression.
- Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
- Subjects who had previous significant gastrointestinal surgeries (e.g. colostomy, colectomy, gastric bypass).
- Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- Subjects of childbearing potential who refuse a pregnancy test.
- Subjects who are allergic to any preparation components
- Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
multi-dose preparation for oral administration prior to colonoscopy
|
multi-dose preparation for oral administration prior to colonoscopy
|
Active Comparator: 2
multi-dose preparation for oral administration prior to colonoscopy
|
multi-dose preparation for oral administration prior to colonoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Preparation Quality Using a 4 Point Scale
Time Frame: 2 days
|
Percentage of patients with a successful preparation (cleaning rated as "Good" or "Excellent")
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Chemistry Results (mEq/L)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Hematology Results (%)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Serum Chemistry Results (U/L)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Serum Chemistry Results (mg/dL)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Serum Chemistry Results (g/dL)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Serum Chemistry Results - Glomerular Filtration Rate
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Hematology Results - Hemoglobin
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Hematology Results (1000/MCL)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Hematology Results - Red Blood Cells
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Serum Chemistry Results (Osmolality)
Time Frame: 2 days
|
Change from Baseline
|
2 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
November 1, 2008
Study Registration Dates
First Submitted
September 18, 2008
First Submitted That Met QC Criteria
September 19, 2008
First Posted (Estimate)
September 22, 2008
Study Record Updates
Last Update Posted (Estimate)
December 27, 2013
Last Update Submitted That Met QC Criteria
December 3, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BLI850-302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on BLI850
-
Braintree LaboratoriesCompletedColon CancerUnited States